エピソード

  • 10/25/24: Low-dose naltrexone in clinical trials
    2024/10/26
    This week, co-hosts Betsy Ladyzhets and Miles Griffis talk with podcast producer James Salanga about clinical trials looking at low-dose naltrexone (LDN) as a potential drug for people living with Long COVID and ME. Also in this episode: the latest COVID-19 numbers, and a new survey of around 70,000 people in China looking at Long COVID, reinfections, and more. The transcript for this podcast is available on The Sick Times' website. You can jump to specific sections of the podcast and transcript below. (00:00:00) Intro (00:01:10) COVID-19 trends (00:03:22) Top story — Low-dose naltrexone clinical trials (00:17:40) Research — Long COVID facts and findings in thousands of Chinese survey participants (00:23:07) Outro and credits Still Here is an abridged version of The Sick Times’ newsletter, which publishes weekly. ⁠Sign up here.⁠ You can also find our podcast on ⁠⁠Apple Podcasts⁠⁠, ⁠⁠Pocket Casts⁠⁠, ⁠⁠Amazon Music⁠⁠, and ⁠⁠iHeartRadio⁠⁠. - Mentioned in this episode (in order of appearance): The Sick Times: National COVID-19 trends, October 22CDC wastewater dashboardBiobot wastewater risk reportsWastewaterSCAN dashboardNature: Daily briefing: COVID protections eliminated a strain of flu CDC: Vaccination Trends | Respiratory IllnessesU.S. free COVID tests: COVID-19 TestingThe Sick Times: Clinical trials explore how Low-Dose Naltrexone could help people with Long COVIDThe Lancet: Regional Health — Western Pacific: Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participantsThe Lancet: Regional Health — Western Pacific: Long Covid is a significant health crisis in China too Research Square: Long COVID and associated outcomes following COVID-19 reinfections: Insights from an International Patient-Led Survey Additional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece) Pixabay: Thunder and the beginning of rainfall
    続きを読む 一部表示
    24 分
  • 10/18/24: New Mount Sinai Long COVID center
    2024/10/19
    This week, co-host Betsy Ladyzhets recaps her reporting tour of the new Long COVID and complex disease center at Mount Sinai, with additional commentary from co-host Miles Griffis. Miles and Betsy also talk with podcast producer James Salanga about the latest COVID-19 numbers. And in research, they share more information about a preprint based on an analysis of 23andMe’s database that suggests genetic associations with Long COVID and a study looking at the cardiac risks associated with COVID-19 infection. The transcript for this podcast is ⁠available on our website⁠. You can jump to specific sections of the transcript and podcast below. (00:00:00) ⁠Intro⁠ (00:01:20) ⁠COVID-19 trends⁠ (00:03:22) Top story — New Mount Sinai complex disease, Long COVID center(00:16:28) ⁠⁠Research — 23andMe genetic associations with Long COVID preprint, study about cardiac risks after SARS-CoV-2 infection⁠(00:19:40) ⁠Outro and credits⁠ Still Here is an abridged version of The Sick Times’ newsletter, which publishes weekly. Sign up here. You can also find our podcast on ⁠Apple Podcasts⁠, ⁠Pocket Casts⁠, ⁠Amazon Music⁠, and ⁠iHeartRadio⁠. - Mentioned in this episode (in order of appearance): The Sick Times: National COVID-19 trends, October 15CDC wastewater dashboardBiobot wastewater risk reportsWastewaterSCAN dashboardU.S. free COVID tests: COVID-19 TestingThe Sick Times: New Long COVID and complex disease center at Mount Sinai set to be a leader in research, clinical careHow to Start a Mask BlocMedRXiV: Multi-ancestry GWAS of Long COVID identifies immune-related loci and etiological links to chronic fatigue syndrome, fibromyalgia and depressionArteriosclerosis, Thrombosis, and Vascular Biology: COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type Additional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece) Pixabay: Thunder and the beginning of rainfallJoshua Roman: Immunity (version included in podcast was recorded live by Betsy)
    続きを読む 一部表示
    21 分
  • 10/11/24: Honoring Tinu Abayomi-Paul
    2024/10/12
    Atinuki “Tinu” Abayomi-Paul was “so funny … and so clever” and “wonderful at supporting disabled people in a beautiful and authentic way.” Several of those who loved and cared for Tinu reflect on her legacy and life in this episode of Still Here. Before the segment of the episode dedicated to honoring Tinu, co-hosts Miles Griffis and Betsy Ladyzhets talk with podcast producer James Salanga about the latest COVID-19 numbers. And they share a brief hopeful update about beginning analysis that could help lead to repurposed drugs as treatment for Long COVID. The transcript for this podcast is available on our website. You can jump to specific sections of the transcript and podcast below. (00:00:00) Intro (00:01:34) COVID-19 trends (00:03:23) Research — CURE ID begins survey analysis (00:07:38) Top story — Honoring Atinuki "Tinu" Abayomi-Paul (00:19:00) Outro and credits You can also find our podcast on Apple Podcasts, Pocket Casts, Amazon Music, and iHeartRadio. - Mentioned in this episode (in order of appearance): The Sick Times: National COVID-19 trends, October 8CDC wastewater dashboardBiobot wastewater risk reportsWastewaterSCAN dashboardThe Sick Times: Research updates, October 8 CUREID: Long COVID surveyThe Sick Times: Long Covid surveys from a FDA/NIH initiative ask which drugs help alleviate symptomsThe Sick Times: Live blog: Following the RECOVER-Treating Long COVID kickoff eventThe Sick Times: “A good step”: Long COVID advocates and researchers respond to the RECOVER-Treating Long COVID meeting The Sick Times: Still Here, October 4: Links and transcriptThe Sick Times: Tinu Abayomi-Paul, writer, disability advocate, and person with Long COVID, dies at 52Creaky Joints: Testing COVID-Positive: My Experience as a Black, Disabled, Immunocompromised WomanGoFundMe: Honoring Tinu’s Legacy With Compassionate Support Additional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece)Pixabay: Thunder and the beginning of rainfallRooted in Rights: Disabled, Not Disposable – TinuNational Disability Rights Network: Tinu Abayomi-Paul
    続きを読む 一部表示
    20 分
  • 10/4/24: Recapping the NIH RECOVER-TLC kickoff
    2024/10/04
    In the pilot episode of Still Here: A Podcast From The Sick Times, co-hosts Miles Griffis and Betsy Ladyzhets talk with podcast producer James Salanga about the latest COVID-19 numbers. Engagement editor Heather Hogan joins James, Miles, and Betsy to recap the NIH RECOVER-TLC meeting from last week. And in research, a hopeful update about a nasal spray effective at blocking respiratory viruses — including COVID-19. The transcript for this podcast is available on our website. You can jump to specific sections of the transcript and podcast below. (00:00:00) Intro (00:02:15) COVID-19 trends (00:04:55) Top story — Recap of NIH RECOVER-TLC meeting and reflections (00:22:15) Research — A nasal spray that performed well in preclinical trials (00:23:00) Outro and credits You can also find our podcast on Apple Podcasts, Pocket Casts, Amazon Music and iHeartRadio. - Mentioned in this episode (in order of appearance): The Sick Times: National COVID-19 trends, October 1CDC wastewater dashboardBiobot wastewater risk reportsWastewaterSCAN dashboardThe Sick Times: ‘They bungled it:’ NIH documents reveal how $1.6 billion Long Covid initiative has failed so far to meet its goalsThe Sick Times: Q&A: NIH Director Dr. Monica Bertagnolli on next steps for RECOVER, future Long COVID research plans, and more The Sick Times: Live blog: Following the RECOVER-Treating Long COVID kickoff eventThe Sick Times: “A good step”: Long COVID advocates and researchers respond to the RECOVER-Treating Long COVID meeting National Academies Press: Global Functioning in Long COVIDJAMA Network: Characterizing Long COVID in Children and AdolescentsThe Sick Times: Five reasons why the NIH should retract the “effort preference” claims in their intramural ME/CFS paperNIH RECOVER websiteRECOVER-TLC: Submit a therapeutic to be considered in a clinical trialHarvard Gazette: Drug-free nasal spray blocks, neutralizes viruses, bacteria Additional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece) Pixabay: Thunder and the beginning of rainfall
    続きを読む 一部表示
    24 分
  • Trailer: Still Here
    2024/10/03

    Learn more about The Sick Times' new podcast, Still Here! Our cover design is from Sophie Dimitriou.

    The Sick Times is a nonprofit newsroom chronicling the ongoing Long COVID crisis.

    Transcript below:

    [instrumental from Rude Mechanical Orchestra’s rendition of “Which Side Are You On?”, orig. Florence Reece, throughout the song]

    Miles: Many public health authorities and media outlets are ignoring the ongoing COVID-19 pandemic.

    Betsy: They’re also failing to cover Long COVID, the most common adverse outcome of COVID-19.

    Miles: I’m Miles Griffis.

    Betsy: And I’m Betsy Ladyzhets. We’re the co-founders of The Sick Times.

    Miles: We are covering the continued Long COVID crisis that affects over four hundred million people globally.

    Betsy: We’ve been bringing you the latest Long COVID news and commentary from our non-profit newsroom since fall 2023.

    Miles: Without pandemic denial, minimizing, or gaslighting.

    Betsy: Now we’re expanding with a new weekly podcast.

    James: We’re calling it Still Here. Because we know disabled people, and COVID, are still here.

    I’m James Salanga, and I’m Still Here’s producer.

    Betsy: Come with us each week as we share the latest on Long COVID and COVID-19 in the United States, give you more context about the stories we’ve published on our website, and highlight new Long COVID research.

    Miles: We’ll bring the information and perspectives you need.

    James: Join us as we continue to hold powerful institutions accountable and amplify the lived experiences of those most impacted by the pandemic.

    Our first episode is coming to a podcast provider near you in early October. Stay tuned!

    続きを読む 一部表示
    1 分